Allogene Therapeutics, Inc. (ALLO)
2.035
-0.06
(-2.63%)
USD |
NASDAQ |
Aug 24, 16:00
2.03
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics EPS Diluted (Quarterly) : -0.1297 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1297 |
| March 31, 2026 | -0.1773 |
| December 31, 2025 | -0.1717 |
| September 30, 2025 | -0.1864 |
| June 30, 2025 | -0.2327 |
| March 31, 2025 | -0.2774 |
| December 31, 2024 | -0.2846 |
| September 30, 2024 | -0.3169 |
| June 30, 2024 | -0.3492 |
| March 31, 2024 | -0.3843 |
| December 31, 2023 | -0.5096 |
| September 30, 2023 | -0.3715 |
| June 30, 2023 | -0.5397 |
| March 31, 2023 | -0.6915 |
| December 31, 2022 | -0.658 |
| September 30, 2022 | -0.5788 |
| June 30, 2022 | -0.5216 |
| March 31, 2022 | -0.5649 |
| Date | Value |
|---|---|
| December 31, 2021 | -0.5249 |
| September 30, 2021 | -0.5706 |
| June 30, 2021 | -0.5261 |
| March 31, 2021 | -0.2498 |
| December 31, 2020 | -0.5281 |
| September 30, 2020 | -0.5207 |
| June 30, 2020 | -0.5285 |
| March 31, 2020 | -0.50 |
| December 31, 2019 | -0.5823 |
| September 30, 2019 | -0.4965 |
| June 30, 2019 | -0.4131 |
| March 31, 2019 | -0.3246 |
| December 31, 2018 | -0.3718 |
| September 30, 2018 | -0.358 |
| June 30, 2018 | -1.166 |
| March 31, 2018 | -0.0214 |
| December 31, 2017 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cartesian Therapeutics, Inc. | 0.4595 |
| Beam Therapeutics, Inc. | -1.176 |
| Kyverna Therapeutics, Inc. | -0.6292 |
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -42.68M |
| Revenue (Quarterly) | 4.64M |
| Total Expenses (Quarterly) | 47.32M |
| Enterprise Value | 468.18M |
| Gross Profit Margin (Quarterly) | 43.00% |
| Profit Margin (Quarterly) | -919.8% |
| Earnings Yield | -32.68% |
| Normalized Earnings Yield | -32.69 |